NON–MUSCLE-INVASIVE BLADDER CANCER: THE ROLE OF MITOMYCIN C IN RECURRENCE MANAGEMENT

Bladder cancer is the tenth most common malignancy worldwide, with non-muscle-invasive bladder cancer (NMIBC) accounting for over three-quarters of cases.The prognosis of NMIBC largely depends on the recurrence and progression rates.Standard treatment for recurrent NMIBC involves transurethral resection of the bladder tumor (TURBT), occasionally followed by chemoablation.Among the available agents, mitomycin C (MMC) has emerged as a promising option.This study aims to compare the efficacy and adverse effects of MMC chemoablation versus TURBT in the management of recurrent NMIBC.A systematic review was conducted in May 2024 using the PubMed, EMBASE, and Cochrane databases.The primary outcomes analyzed included the occurrence of cystitis, dysuria, hematuria, incontinence, and complete response to treatment.Only randomized, placebocontrolled trials were included.The search terms used were: (Chemoablation OR Chemoresection OR "Mitomycin-C") AND ("Non-muscle-invasive Bladder Cancer" OR NMIBC OR "Bladder Cancer").The risk of bias was assessed using the Revised Cochrane Risk of Bias Tool for Randomized Trials (RoB 2).